05/05/2025 – AB Science announced that new analyses from its phase 3 trial in ALS and preclinical animal model data have been accepted for presentation at the ENCALS annual meeting (June 3-6, 2025, Turin, Italy) Download PDF Post navigationPreviousPrevious post:AB Science will publish its 2024 annual financial report on May 9, 2025NextNext post:Annual financial results as of 31 December, 2024Related PostsAB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025AB Science announces the successful completion of a 2.55 million euros private placementAugust 4, 2025AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AMLJuly 30, 2025AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025AB Science announces the successful completion of a EUR 1.925 million private placementJuly 8, 2025Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025
AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
AB Science announces the successful completion of a 2.55 million euros private placementAugust 4, 2025
AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AMLJuly 30, 2025
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025
Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025
